Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Many people taking Ozempic and related drugs have reported mental health concerns. Those side effects aren't in Ozempic's instructions for use. Are the problems a coincidence or related to the drug? -
The science of baby babble is surprisingly complex. And the idea that a baby exposed to two languages will be confused? Let's see what babble researchers have to say about that.
-
The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drugmakers are fighting the negotiations with lawsuits.
-
The Food and Drug Administration has approved the first vaccine for expectant mothers to shield their babies from RSV.
-
A tornado that ripped through a Pfizer plant in Rocky Mount, N.C., raised worries about shortages of medicines used in hospitals. The drugs include commonly used painkillers and anesthetics.
-
A Texas judge ruled that the Food and Drug Administration wrongly approved mifepristone in 2000 and accused it of doing a rush job. Here's what really went down.
-
Strep throat is more prevalent this year, and amoxicillin manufacturers didn't make enough of the antibiotic to go around.
-
Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that's not enough help.
-
The Food and Drug Administration has new tools to hold drug companies accountable for promises they make about medications. But the agency has yet to show its hand in using this new power.
-
The FDA announced the supply troubles in the fall. Four months later, the medication remains hard to get and could stay that way until the spring
-
The FDA announced the supply troubles in the fall. Four months later, the medication remains hard to get and could stay that way until the spring
-
At-home rapid tests have become a staple of COVID-19 precautions, but some experts worry that people are relying too much on these tests and that's creating a false sense of security.
